7.6.3	  Summary of evidence and guidelines for adjuvant therapy,
Summary of evidence,LE
"In a first-line setting, PS and the presence or absence of visceral metastases are independent   prognostic factors for survival.",1b
"In a second-line setting, negative prognostic factors are: liver metastasis, PS > 1 and low haemoglobin   (< 10 g/dL).",1b
"Cisplatin-containing combination chemotherapy can achieve median survival of up to 14 months, with   long-term DFS reported in ~15% of patients with nodal disease and good PS.",1b
Single-agent chemotherapy provides low response rates of usually short duration.,2a
